US FDA Has Granted A “Rare Pediatric Disease Drug” Designation for NV-387 As A Treatment for Measles – Enables Priority Review Voucher
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"),...
Hemostemix to Highlight Commercial Phase I Longevity Treatment at Small Cap Growth Investor Conference